Drug company Valeant described as ‘poster child for pharmaceutical greed’
By Nadia Prupis, staff writer for Common Dreams. Published 10-14-2016

“While kids in Flint are poisoned by lead, Valeant charges $27,000 for the leading treatment,” Sanders wrote. (Photo: Partha S. Sahana/flickr/cc)
Outrage is growing this week amid revelations that the pharmaceutical company Valeant raised the price for its critical lead-poisoning treatment by more than 2,700 percent in a single year.
Before Valeant took control of the medication, known as Calcium EDTA, in 2013, the average price for a package of vials was stable at $950, the medical news outlet STAT reported. But once the notorious pharmaceutical company bought it out in a multi-billion dollar deal, it swiftly boosted the price to $7,116 in January 2014 and to $26,927 by December of that year. Continue reading